Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress
Parkinson disease (PD) is the second most common neurodegenerative disease without known disease modification therapy to slow down disease progression. This disease has pathological features of Lewy bodies with α-synuclein aggregation being the major component and selective dopaminergic neuronal los...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292641/ https://www.ncbi.nlm.nih.gov/pubmed/34305527 http://dx.doi.org/10.3389/fnmol.2021.697440 |
_version_ | 1783724867606020096 |
---|---|
author | Lin, Tsu-Kung Lin, Kai-Jung Lin, Hung-Yu Lin, Kai-Lieh Lan, Min-Yu Wang, Pei-Wen Wang, Tzu-Jou Wang, Feng-Sheng Tsai, Po-Chin Liou, Chia-Wei Chuang, Jiin-Haur |
author_facet | Lin, Tsu-Kung Lin, Kai-Jung Lin, Hung-Yu Lin, Kai-Lieh Lan, Min-Yu Wang, Pei-Wen Wang, Tzu-Jou Wang, Feng-Sheng Tsai, Po-Chin Liou, Chia-Wei Chuang, Jiin-Haur |
author_sort | Lin, Tsu-Kung |
collection | PubMed |
description | Parkinson disease (PD) is the second most common neurodegenerative disease without known disease modification therapy to slow down disease progression. This disease has pathological features of Lewy bodies with α-synuclein aggregation being the major component and selective dopaminergic neuronal loss over the substantia nigra. Although the exact etiology is still unknown, mitochondrial dysfunction has been shown to be central in PD pathophysiology. Type 2 diabetes mellitus has recently been connected to PD, and anti-diabetic drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), have been shown to possess neuroprotective effects in PD animal models. The GLP-1RA liraglutide is currently under a phase 2 clinical trial to measure its effect on motor and non-motor symptoms in PD patients. In this study, we used an acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD to test the possible mechanism of the GLP-1RA liraglutide in the pathogenesis of PD. We show that the neurobehavioral and motor dysfunction caused by the mitochondrial complex I inhibitor, MPTP, can be partially reversed by liraglutide. The GLP-1RA can protect mice from apoptosis of substantia nigra neurons induced by MPTP. MPTP treatment led to imbalanced mitochondrial fusion and fission dynamics, altered mitochondrial morphology, impeded autophagy flux, increased α-synuclein accumulation, and elevated oxidative stress. Specifically, the normalizing of mitochondrial fusion-fission dynamic-related proteins and enhancement of autophagy flux after administration of liraglutide is associated with improving neuronal survival. This suggests that GLP-1RAs may provide potential beneficial effects for PD caused by mitochondrial dysfunction through improvement of mitochondrial morphology balance and enhancing damaged organelle degradation. |
format | Online Article Text |
id | pubmed-8292641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82926412021-07-22 Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress Lin, Tsu-Kung Lin, Kai-Jung Lin, Hung-Yu Lin, Kai-Lieh Lan, Min-Yu Wang, Pei-Wen Wang, Tzu-Jou Wang, Feng-Sheng Tsai, Po-Chin Liou, Chia-Wei Chuang, Jiin-Haur Front Mol Neurosci Molecular Neuroscience Parkinson disease (PD) is the second most common neurodegenerative disease without known disease modification therapy to slow down disease progression. This disease has pathological features of Lewy bodies with α-synuclein aggregation being the major component and selective dopaminergic neuronal loss over the substantia nigra. Although the exact etiology is still unknown, mitochondrial dysfunction has been shown to be central in PD pathophysiology. Type 2 diabetes mellitus has recently been connected to PD, and anti-diabetic drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), have been shown to possess neuroprotective effects in PD animal models. The GLP-1RA liraglutide is currently under a phase 2 clinical trial to measure its effect on motor and non-motor symptoms in PD patients. In this study, we used an acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD to test the possible mechanism of the GLP-1RA liraglutide in the pathogenesis of PD. We show that the neurobehavioral and motor dysfunction caused by the mitochondrial complex I inhibitor, MPTP, can be partially reversed by liraglutide. The GLP-1RA can protect mice from apoptosis of substantia nigra neurons induced by MPTP. MPTP treatment led to imbalanced mitochondrial fusion and fission dynamics, altered mitochondrial morphology, impeded autophagy flux, increased α-synuclein accumulation, and elevated oxidative stress. Specifically, the normalizing of mitochondrial fusion-fission dynamic-related proteins and enhancement of autophagy flux after administration of liraglutide is associated with improving neuronal survival. This suggests that GLP-1RAs may provide potential beneficial effects for PD caused by mitochondrial dysfunction through improvement of mitochondrial morphology balance and enhancing damaged organelle degradation. Frontiers Media S.A. 2021-07-07 /pmc/articles/PMC8292641/ /pubmed/34305527 http://dx.doi.org/10.3389/fnmol.2021.697440 Text en Copyright © 2021 Lin, Lin, Lin, Lin, Lan, Wang, Wang, Wang, Tsai, Liou and Chuang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Neuroscience Lin, Tsu-Kung Lin, Kai-Jung Lin, Hung-Yu Lin, Kai-Lieh Lan, Min-Yu Wang, Pei-Wen Wang, Tzu-Jou Wang, Feng-Sheng Tsai, Po-Chin Liou, Chia-Wei Chuang, Jiin-Haur Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress |
title | Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress |
title_full | Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress |
title_fullStr | Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress |
title_full_unstemmed | Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress |
title_short | Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress |
title_sort | glucagon-like peptide-1 receptor agonist ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) neurotoxicity through enhancing mitophagy flux and reducing α-synuclein and oxidative stress |
topic | Molecular Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292641/ https://www.ncbi.nlm.nih.gov/pubmed/34305527 http://dx.doi.org/10.3389/fnmol.2021.697440 |
work_keys_str_mv | AT lintsukung glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT linkaijung glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT linhungyu glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT linkailieh glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT lanminyu glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT wangpeiwen glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT wangtzujou glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT wangfengsheng glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT tsaipochin glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT liouchiawei glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress AT chuangjiinhaur glucagonlikepeptide1receptoragonistameliorates1methyl4phenyl1236tetrahydropyridinemptpneurotoxicitythroughenhancingmitophagyfluxandreducingasynucleinandoxidativestress |